Berberine

Berberine is a yellow plant alkaloid used in traditional medicine systems and now sold for blood sugar, cholesterol and weight. Evidence for glucose and lipid measures is reasonable in quantity but limited in quality, and the compound behaves pharmacologically enough to interact with medicines.

Berberine hydrochloride is the usual supplement form. Oral absorption is poor, which is why products use higher amounts, split dosing, or modified forms such as dihydroberberine.

Berberine activates AMP-activated protein kinase, an energy-sensing pathway, and affects glucose uptake, liver glucose output, LDL receptor expression and the gut microbiome.

Randomised trials, mostly small and largely conducted in China, report reductions in fasting glucose, HbA1c, LDL cholesterol and triglycerides, sometimes comparable to low-dose standard medicines. Weight-loss effects are small. Long-term safety and hard outcome data — such as cardiovascular events — are not available.

Cell and animal studies describe AMPK activation, effects on hepatic glucose production, lipid handling, gut bacteria and inflammatory signalling.

Evidence gap: Non-human evidence. It supports mechanism only and does not demonstrate human clinical benefit.

Berberine slows the breakdown of several medicines and adds to the effect of glucose-lowering drugs, which can cause low blood sugar. Gastrointestinal effects are common at higher amounts.

The most common effects are diarrhoea, constipation, cramping and nausea. The main clinical risk is low blood sugar when it is added to diabetes medicines without adjusting them or monitoring. Berberine must not be used in pregnancy or breastfeeding and not given to newborns, because it can displace bilirubin and has been associated with kernicterus risk in infants. Liver enzyme changes have been reported occasionally. It is not appropriate as a self-directed replacement for prescribed diabetes, cholesterol or weight treatment.

Capsules and tablets of berberine HCl, usually taken in divided doses with meals, are the researched form.

For glucose and lipids, established approaches are dietary pattern change, physical activity, weight management where appropriate, and prescribed medicines such as metformin or statins with monitoring. Berberine is being studied as an adjunct and is not a replacement for those, nor for medical assessment of diabetes or cardiovascular risk.

Educational example: a person on a sulfonylurea adds berberine after seeing it described online as natural metformin and experiences repeated low blood sugar episodes. Decision factors are existing glucose-lowering therapy, monitoring, and whether the clinician knows. Questions to ask: could this lower my blood sugar too far, does it affect my other medicines, and how should I monitor? Comparing berberine to prescription drugs in marketing is a recognised misinformation pattern; pregnancy and infant risk is frequently omitted.